Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.
|Original language||English (US)|
|Journal||ONCOLOGY (United States)|
|State||Published - Jun 15 2015|
ASJC Scopus subject areas
- Cancer Research